View Future GrowthGenus 過去の業績過去 基準チェック /16Genusの収益は年間平均-19.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 4%割合で 増加しています。 Genusの自己資本利益率は9.5%であり、純利益率は7.1%です。主要情報-19.15%収益成長率-19.46%EPS成長率Biotechs 業界の成長17.04%収益成長率4.05%株主資本利益率9.47%ネット・マージン7.07%次回の業績アップデート10 Sep 2026最近の業績更新お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025お知らせ • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Nov 24+ 1 more updateGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024すべての更新を表示Recent updatesお知らせ • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026お知らせ • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.お知らせ • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdomお知らせ • Sep 04Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025.お知らせ • May 02Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig ProgrammeGenus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%.お知らせ • Mar 13+ 1 more updateGenus plc Appoints Andy Russell as Chief Financial Officer, Effective August 1, 2025The Board of Genus plc announced that it has appointed Andy Russell as Chief Financial Officer. Andy will commence with Genus and join the Board on 1 August 2025, taking over from Alison Henriksen after she retires from the Company on 31 July 2025, after more than five years in the role. Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects). Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.お知らせ • Feb 26Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.お知らせ • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025お知らせ • Nov 21Genus plc Declares A Final DividendGenus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024.お知らせ • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Oct 22Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.お知らせ • Sep 05Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024.お知らせ • Nov 24+ 1 more updateGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024収支内訳Genus の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:GENS.Y 収益、費用、利益 ( )GBP Millions日付収益収益G+A経費研究開発費31 Dec 25672481297230 Sep 25672331287230 Jun 25673191277231 Mar 2567281217531 Dec 24672-41157930 Sep 2467021167930 Jun 2466981167931 Mar 24671211147831 Dec 23673331117730 Sep 23681331117730 Jun 23690331107731 Mar 23676341007531 Dec 2266234907330 Sep 2262838897330 Jun 2259341897331 Mar 2258239927131 Dec 2157037956830 Sep 2157242966830 Jun 2157447976831 Mar 2157045937031 Dec 2056642897130 Sep 2055939897130 Jun 2055135887131 Mar 2053637806631 Dec 1952039726130 Sep 1950423726130 Jun 194898726131 Mar 194801765631 Dec 18471-7815130 Sep 1847018815130 Jun 1847043825131 Mar 1847355804831 Dec 1747667794530 Sep 1746750794530 Jun 1745933784531 Mar 1744140754031 Dec 1642247713430 Sep 1640548713430 Jun 1638849713431 Mar 1638840683231 Dec 1538831642930 Sep 1539335642930 Jun 15399406429質の高い収益: GENS.Yには£17.3M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st December, 2025に影響を及ぼしています。利益率の向上: GENS.Y過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: GENS.Yの収益は過去 5 年間で年間19.2%減少しました。成長の加速: GENS.Yは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: GENS.Y昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: GENS.Yの 自己資本利益率 ( 9.5% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 19:16終値2026/05/21 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genus plc 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Robert ChantryBerenbergMatthew LloydBNP ParibasAlexander JonesBofA Global Research15 その他のアナリストを表示
お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026
お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025
お知らせ • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Nov 24+ 1 more updateGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024
お知らせ • Jan 24+ 1 more updateHealth Canada and CFIA Announce Completion of Safety Assessments on PRRSV-Resistant Pigs from Genus PLC and PIC Canada, LtdHealth Canada and the Canadian Food Inspection Agency (CFIA) announced the completion of independent, comprehensive safety assessments on pigs resistant to PRRSV following applications from Genus PLC and PIC Canada Ltd., respectively. Health Canada has concluded that foods made from these pigs are as safe and nutritious for people to eat as pork currently available in Canada. The CFIA has confirmed that these pigs are also safe and effective for use in livestock feeds. Improving resistance to PRRSV in pigs will help farmers avoid illness in their herds from these viruses, reduce antibiotic use, and improve animal welfare, while supporting a more stable, affordable and sustainable food supply. Genus PLC's PRRSV-resistant pigs are already permitted for food use in the U.S., Brazil, Colombia and the Dominican Republic. Genus PLC has indicated that even though Canada has approved the sale of PRRSV resistant pigs, the company does not intend to sell these pigs before further regulatory authorization in other key markets. The company and Health Canada are committed to the highest level of transparency and will communicate to the public when this new technology enters the Canadian market. While genetically engineered foods are considered as safe and nutritious as conventional foods, the Government of Canada recognizes that information about genetic engineering is important. That is why have been working with the Canadian General Standards Board since November on a public review of the National Standard for labelling and advertising of foods that are, and are not, products of genetic engineering. The CFIA uses this Standard to provide its guidance to companies on the labelling of foods.
お知らせ • Jan 08Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026
お知らせ • Nov 21+ 1 more updateGenus plc Approves to Appoint Andrew Russell as A DirectorGenus plc announced that at its AGM held on 19 November 2025, the shareholder approved to elect Andrew Russell as a Director of the Company.
お知らせ • Nov 20Genus plc Announces Board AppointmentsGenus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.
お知らせ • Nov 19Genus plc to Report First Half, 2026 Results on Feb 26, 2026Genus plc announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Oct 10Genus plc, Annual General Meeting, Nov 19, 2025Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom
お知らせ • Sep 04Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025.
お知らせ • May 02Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig ProgrammeGenus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%.
お知らせ • Mar 13+ 1 more updateGenus plc Appoints Andy Russell as Chief Financial Officer, Effective August 1, 2025The Board of Genus plc announced that it has appointed Andy Russell as Chief Financial Officer. Andy will commence with Genus and join the Board on 1 August 2025, taking over from Alison Henriksen after she retires from the Company on 31 July 2025, after more than five years in the role. Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects). Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.
お知らせ • Feb 26Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.
お知らせ • Nov 30Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025
お知らせ • Nov 21Genus plc Declares A Final DividendGenus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024.
お知らせ • Nov 20Genus plc to Report First Half, 2025 Results on Feb 27, 2025Genus plc announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Oct 22Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.
お知らせ • Sep 05Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024.
お知らせ • Nov 24+ 1 more updateGenus plc to Report Fiscal Year 2024 Results on Sep 05, 2024Genus plc announced that they will report fiscal year 2024 results on Sep 05, 2024